Quality Healthcare Management INC

Quality Healthcare Management INC was paid $22.26M by Medicaid between Jan 2018 and Dec 2024, across 280 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 8.9% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#16 of 116

Median peer was paid$618K

This provider vs. median36×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	654,740	$3.20M
2019	875,375	$4.25M
2020	653,570	$3.88M
2021	706,966	$4.39M
2022	723,049	$3.60M
2023	498,665	$2.04M
2024incomplete	193,013	$894K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	8.9%	25,353	13,851	$1.99M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	8.2%	39,278	33,402	$1.83M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.4%	115,946	70,756	$1.21M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.5%	52,649	49,677	$790K
80364		2.2%	97,958	59,294	$498K
80348		2.0%	96,774	58,681	$438K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.9%	4,073	2,253	$421K
86481		1.8%	14,051	13,273	$396K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.7%	26,404	21,644	$386K
80323		1.7%	96,235	57,522	$379K
80050	General health panel	1.7%	19,440	19,058	$374K
86769		1.7%	15,320	14,795	$373K

268 more codes

80053	Comprehensive metabolic panel	1.6%	76,183	$349K
80365		1.4%	97,042	$320K
82607		1.4%	50,343	$315K
83036	Hemoglobin; glycosylated (A1C)	1.4%	70,362	$313K
80361		1.4%	94,276	$308K
80356		1.4%	98,158	$306K
83992		1.4%	86,850	$303K
80349		1.3%	96,789	$297K
80061	Lipid panel	1.3%	78,023	$291K
80358		1.3%	96,422	$290K
80353		1.3%	97,856	$284K
80346		1.3%	93,054	$279K
80359		1.3%	97,022	$279K
84443	Thyroid stimulating hormone (TSH)	1.2%	59,429	$277K
80324		1.2%	95,904	$276K
80350		1.2%	86,781	$273K
80338		1.1%	71,739	$252K
80370		1.1%	61,160	$236K
87631		1.1%	5,147	$236K
80375		1.0%	78,016	$230K
80345		<1%	79,334	$219K
80335		<1%	84,518	$218K
82746		<1%	39,035	$210K
84439		<1%	47,220	$205K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	15,125	$188K
80372		<1%	78,617	$178K
80360		<1%	81,799	$174K
82728		<1%	29,568	$174K
80357		<1%	81,985	$173K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	15,195	$171K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	24,398	$169K
80366		<1%	76,515	$167K
80373		<1%	77,827	$167K
80368		<1%	75,830	$166K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	11,850	$166K
80355		<1%	76,458	$156K
80321		<1%	46,634	$154K
84481		<1%	25,719	$139K
80371		<1%	62,031	$135K
86803		<1%	23,179	$133K
84153		<1%	13,913	$132K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	75,583	$128K
82652		<1%	12,356	$123K
80354		<1%	76,132	$119K
87340		<1%	21,918	$107K
80332		<1%	50,291	$103K
86706		<1%	22,799	$101K
86780		<1%	16,095	$101K
84403		<1%	7,686	$98K
86703		<1%	12,796	$95K
86704		<1%	18,528	$92K
80336		<1%	21,841	$83K
83013		<1%	2,578	$82K
81001		<1%	57,355	$77K
83970		<1%	3,247	$73K
86708		<1%	15,413	$72K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,518	$71K
80436		<1%	3,279	$71K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	7,408	$68K
86696		<1%	8,871	$67K
83550		<1%	28,445	$67K
83540		<1%	32,094	$66K
87581		<1%	7,796	$65K
84402		<1%	5,201	$62K
86003		<1%	1,520	$60K
84550		<1%	30,149	$55K
87086	Culture, bacterial; quantitative colony count, urine	<1%	14,415	$50K
83880		<1%	3,564	$50K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	981	$50K
80320		<1%	15,590	$48K
87486		<1%	6,383	$46K
87522	Neg quan hep c or qual rna	<1%	1,887	$44K
86762		<1%	6,073	$41K
82570		<1%	24,055	$40K
82378		<1%	3,875	$39K
82670		<1%	2,935	$38K
86765		<1%	6,173	$37K
83735		<1%	16,512	$36K
86141		<1%	6,614	$35K
82043		<1%	16,614	$35K
86376		<1%	5,596	$34K
86800		<1%	5,445	$34K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	2,015	$33K
83001		<1%	3,673	$33K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	4,025	$33K
83002		<1%	3,581	$32K
84146		<1%	3,028	$31K
84436		<1%	21,556	$30K
82248		<1%	14,152	$27K
86038		<1%	9,255	$26K
84480		<1%	15,022	$26K
82785		<1%	2,988	$25K
86735		<1%	5,642	$25K
83655		<1%	3,684	$24K
84144		<1%	2,400	$24K
83090		<1%	3,344	$24K
84154		<1%	2,700	$23K
87184		<1%	4,369	$22K
86787		<1%	5,073	$22K
87070		<1%	5,585	$21K
84702		<1%	3,639	$21K
86140		<1%	12,645	$20K
86431		<1%	9,255	$19K
84270		<1%	5,483	$19K
86695		<1%	6,725	$19K
82977		<1%	9,244	$18K
85651		<1%	17,781	$17K
84479		<1%	18,659	$17K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	547	$17K
86480		<1%	598	$17K
84207		<1%	1,266	$17K
87088		<1%	4,238	$16K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	2,259	$16K
86060		<1%	7,302	$15K
86618		<1%	641	$15K
86593		<1%	7,065	$14K
88142		<1%	1,456	$14K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,144	$14K
83721		<1%	5,058	$13K
85046		<1%	13,398	$13K
85730		<1%	4,278	$11K
84100		<1%	6,069	$11K
82784		<1%	819	$11K
83690		<1%	3,946	$11K
80171		<1%	3,463	$10K
84425		<1%	1,428	$10K
82627		<1%	1,101	$10K
85610		<1%	5,319	$9K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,376	$9K
82533		<1%	1,454	$9K
83921		<1%	1,005	$9K
83615		<1%	4,215	$9K
88112		<1%	604	$9K
82550		<1%	3,779	$9K
86235		<1%	1,048	$8K
82150		<1%	3,642	$7K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	1,687	$7K
82180		<1%	1,504	$7K
86619		<1%	566	$6K
84466		<1%	1,005	$5K
87420		<1%	1,397	$5K
86304		<1%	603	$5K
36415	Collection of venous blood by venipuncture	<1%	10,173	$4K
84445		<1%	477	$4K
84311		<1%	4,267	$4K
80362		<1%	3,204	$4K
84378		<1%	661	$4K
86665		<1%	385	$4K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	504	$4K
82985		<1%	1,899	$3K
83525		<1%	922	$3K
86225		<1%	1,276	$3K
85027		<1%	1,472	$3K
82105		<1%	886	$3K
84315		<1%	4,612	$3K
87210		<1%	1,742	$3K
86301		<1%	389	$3K
82553		<1%	598	$3K
83021		<1%	205	$2K
86705		<1%	658	$2K
84681		<1%	208	$2K
83986		<1%	4,206	$2K
80076		<1%	2,855	$2K
84252		<1%	1,102	$2K
82108		<1%	152	$2K
80074		<1%	207	$2K
83520		<1%	840	$2K
82525		<1%	291	$2K
84255		<1%	328	$2K
84630		<1%	519	$2K
84590		<1%	346	$2K
82175		<1%	161	$2K
86039		<1%	699	$1K
86900		<1%	891	$1K
82495		<1%	138	$1K
83825		<1%	164	$1K
83516		<1%	896	$1K
86677		<1%	289	$1K
82300		<1%	149	$1K
82542		<1%	1,475	$1K
86664		<1%	179	$1K
84446		<1%	292	$1K
84484		<1%	267	$1K
82465		<1%	708	$1K
86901		<1%	716	$1K
86709		<1%	916	$1K
82274		<1%	628	$1K
87205		<1%	593	$1K
86663		<1%	179	$1K
86160		<1%	130	$931.73
82157		<1%	45	$921.22
87660		<1%	83	$835.35
84432		<1%	728	$826.43
87480		<1%	83	$807.45
87510		<1%	68	$759.67
86644		<1%	119	$664.30
81025		<1%	639	$660.09
85379		<1%	134	$613.20
80369		<1%	384	$473.89
82390		<1%	115	$449.57
84305		<1%	140	$428.91
86645		<1%	109	$414.33
84156		<1%	400	$411.60
87276		<1%	41	$391.93
87275		<1%	41	$373.21
82330		<1%	131	$330.66
86200		<1%	73	$326.36
84591		<1%	271	$314.25
86300		<1%	25	$270.12
82024		<1%	12	$258.20
86334		<1%	16	$251.59
84703		<1%	138	$204.59
80164		<1%	96	$200.28
83519		<1%	23	$196.00
85007		<1%	904	$194.39
87045		<1%	52	$175.18
80069		<1%	108	$169.90
83883		<1%	16	$157.48
86255		<1%	27	$147.37
83003		<1%	17	$133.66
82085		<1%	154	$132.00
87077		<1%	27	$130.62
87147		<1%	168	$120.98
86774		<1%	433	$118.59
82672		<1%	17	$109.41
86632		<1%	19	$101.94
82947		<1%	100	$100.28
86631		<1%	19	$99.22
86648		<1%	410	$92.16
82164		<1%	123	$89.88
86707		<1%	15	$79.46
85048		<1%	593	$70.28
86021		<1%	265	$65.17
82172		<1%	43	$64.37
86258		<1%	16	$62.82
84075		<1%	39	$62.10
84478		<1%	85	$60.42
87109		<1%	16	$57.67
84165		<1%	17	$56.81
87075		<1%	14	$50.60
82310		<1%	33	$50.51
82247		<1%	42	$50.21
84155		<1%	58	$49.97
84460		<1%	33	$45.27
84450		<1%	32	$45.27
82040		<1%	39	$44.55
86364		<1%	14	$41.09
82565		<1%	27	$39.74
81000		<1%	68	$37.20
82945		<1%	12	$35.37
84520		<1%	26	$32.18
84132		<1%	53	$30.34
83718		<1%	62	$21.58
82374		<1%	48	$19.52
84295		<1%	46	$19.24
82435		<1%	48	$18.40
85660		<1%	14	$18.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	18	$17.17
84482		<1%	36	$11.52
82523		<1%	22	$9.34
3044F		<1%	7,047	$7.00
82380		<1%	28	$3.87
3052F		<1%	253	$1.00
99080		0%	465	$0.00
83695		0%	89	$0.00
3046F		0%	426	$0.00
3051F		0%	643	$0.00
82610		0%	30	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKHARAZ, ALEXANDER (CHIEF OPERATING OFFICER)